Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors

Neurological Sciences

Volumn 23, Issue SUPPL. 2, 2002, Pages

  Parnetti, L ^a   Amici, S ^a   Lanari, A ^a   Romani, C ^a   Antognelli, C ^a   Andreasen, N ^b   Minthon, L ^c   Davidsson, P ^d   Pottel, H ^b   Blennow, K ^d   Gallai, V ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Department of Rehabilitation ^*

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BIOCHEMISTRY; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALANTAMINE; HUMANS; INDANS; PEPTIDE FRAGMENTS; PHENYLCARBAMATES; PHOSPHORYLATION; PIPERIDINES; TAU PROTEINS;

EID: 18744417222     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720200086     Document Type: Article

References (8)

1. Mori F, Lai CC, Fusi F, Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in brain cortex. Neuroreport 6:633-636
2. Inestrosa NC, Alvarez A, Perez CA et al (1996) Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possibile role of the peripheral site of the enzyme. Neuron 16:881-891
3. Saez-Valero J, Sberna G, McLean CA, Small DH (1999) Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 72:1600-1608
4. Hellstrom-Lindahl E, Moore H, Nordberg A (2000) Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74:777-784
5. Parnetti L, Lanari A, Amici S et al (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci 22:77-78
6. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C (2001) Differential increase in cerebrospinal fluid acetylcholine esterase after treatment with acetylcholine esterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 16:157-160
7. Amici S, Lanari A, Romani R et al (2001) Cerebrospinal fluid acetylcholinesterase activity after long term treatment with donepezil and rivastigmine. Mech Ageing Dev 122:2057-2062
8. Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Therapeutics 20:634-647